• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Empagliflozin use is associated with slower progression of chronic kidney disease

byDavid XiangandKiera Liblik
January 26, 2023
in Cardiology, Chronic Disease, Nephrology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Empagliflozin led to a lower risk of kidney disease progression in patients with chronic kidney disease (CKD) as compared to placebo control.

2. Compared to placebo, empagliflozin was associated with a lower risk of death from cardiovascular causes in patients with CKD.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Chronic kidney disease (CKD) is a progressive disease. Slowing the disease process while avoiding the need for dialysis or kidney transplant is one of the primary goals of care. Notably, dialysis and kidney transplantation have significant impacts on the quality of life and cardiovascular morbidity and mortality. Sodium-glucose Cotransporter-2 (SGLT2) inhibitors have been shown to reduce the risk of progression to kidney failure in patients with diabetic kidney disease. There is a gap in knowledge as to understanding how empagliflozin, an SGLT2 inhibitor, would impact CKD progression in patients with an estimated glomerular filtration rate (GFR) of less than 30 ml per minute per 1.73 m^2 of body-surface area. Overall, this study found that compared to placebo, empagliflozin treatment led to a lower risk of progression of kidney disease or death from cardiovascular causes in patients across a broad range of CKD. This included patients without diabetes, with an estimated GFR of less than 30 ml per minute per 1.73 m^2, and with a low urinary albumin-to-creatinine ratio. This study was limited by a lower-than-expected number of cardiovascular events, which reduced the statistical power for the assessment of the secondary and tertiary cardiovascular outcomes. Nevertheless, these study’s findings are significant, as they demonstrate that empagliflozin provides a significantly reduced risk of CKD progression and lower risk of cardiovascular-related death.

Click to read the study in NEJM

Relevant Reading: Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

In-Depth [randomized controlled trial]: This randomized, parallel-group, double-blind, placebo-controlled clinical trial was conducted at 241 centers across eight countries. Patients who were adults with a race-adjusted eGFR (calculated with the use of the Chronic Kidney Disease Epidemiology Collaboration formula) of at least 20 but less than 45 ml per minute per 1.73 m^2, regardless of the level of albuminuria, or with an eGFR of at least 45 but less than 90 ml per minute per 1.73 m^2 with a urinary albumin to- creatinine ratio of at least 200 were eligible for the study. Patients with or without diabetes were also eligible. Patients with polycystic kidney disease and those who had received kidney transplants were excluded from the study. The primary outcome measured was the first occurrence of the progression of kidney disease or death from cardiovascular causes. Progression of kidney disease was defined as end-stage kidney disease (ESKD; the initiation of maintenance dialysis or receipt of a kidney transplant), a sustained decrease in the eGFR to less than 10 ml per minute per 1.73 m^2, or a sustained decrease from baseline in the eGFR of at least 40%, or death from renal causes. Outcomes in the primary analysis were assessed via the intention-to-treat principle and a Cox proportional hazards regression model was used. Based on the primary analysis, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3,304 patients (13.1%) in the empagliflozin group and in 558 of 3,305 patients (16.9%) in the placebo group (Hazard Ratio [HR], 0.72; 95% Confidence Interval [CI], 0.64 to 0.82). Results were consistent among patients regardless of diabetes status. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (HR, 0.86; 95% CI, 0.78 to 0.95), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure, death from cardiovascular causes, or death from any cause. The present study demonstrated that SGLT2 inhibitors may represent an effective management strategy for preventing worsening renal and cardiovascular function in CKD patients.

RELATED REPORTS

Hydrochlorothiazide does not impact risk of kidney-stone recurrence

Synergistic interaction between risk burden and genetics for atrial fibrillation development

Nivolumab plus ipilimumab does not improve survival in post-nephrectomy patients with renal cell carcinoma

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cardiologycardiovascular mortalitychronic diseasechronic kidney diseasedialysisempagliflozininternal medicinenephrologyRenal dysfunctionSGLT2sglt2 inhibitorsSGLT2i
Previous Post

Diagnostic tool may help identify cerebral palsy regardless of encephalopathy features

Next Post

Chronic obstructive pulmonary disease associated with worse postoperative outcomes

RelatedReports

Renal stones in women linked with increased risk of coronary heart disease
Nephrology

Hydrochlorothiazide does not impact risk of kidney-stone recurrence

March 22, 2023
Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source
Cardiology

Synergistic interaction between risk burden and genetics for atrial fibrillation development

March 21, 2023
Tenofovir disoprovil fumarate HIV prophylaxis linked with minimal kidney impact
Chronic Disease

Nivolumab plus ipilimumab does not improve survival in post-nephrectomy patients with renal cell carcinoma

March 21, 2023
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Chronic Disease

Symptom and viral relapse more common in COVID-19 patients without antiviral treatment

March 21, 2023
Next Post
2 Minute Medicine Rewind May 20, 2019

Chronic obstructive pulmonary disease associated with worse postoperative outcomes

#VisualAbstract: Telehealth treatment is effective in managing behavior problems in children with developmental delay

#VisualAbstract: Adagrasib provides antitumour activity against KRAS G12C mutant metastatic colorectal cancer both as monotherapy and in combination with cetuximab

Vegetarian diet may lower incidence of colorectal cancer

Plant-based diets may be associated with lower risk of aggressive prostate cancer

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Mycobacterium abscessus infections after cardiac surgery linked to hospital water system
  • The 2 Minute Medicine Podcast Episode 11
  • Wellness Check: Spirituality
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options